ABBV AbbVie Inc.
$293.30
AbbVie Inc. (ABBV) is expected to report earnings on January 29, 2027, before the market open. The consensus earnings estimate is $3.90 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.5% since its last earnings release on October 30, 2026.
AbbVie Beat Consensus Estimates, Narrows Guidance
Friday, October 30, 2026 · 7:46 AM ET
Earnings Date
4th Quarter, Dec 2026
Jan 29
Friday · 7:45 AM ET
Earnings Whisper
-
vs $3.90
Rev est $18.44B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$290.83
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About AbbVie Inc.
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn' disease, HIV, cystic fibrosis complications.
Sector
Healthcare
Industry
Drug Manufacturers / Major
Held By 9 ETFs, by dollar flow
- XT iShares Exponential Technologies ETF
- OEF iShares S&P 100 ETF
- XLG Invesco S&P 500 Top 50 ETF
- IYH iShares U.S. Healthcare ETF
- HDV iShares Core High Dividend ETF
- XLV Health Care Select Sector SPDR Fund
- IXJ iShares Global Healthcare ETF
- BMED iShares Health Innovation Active ETF
- PPH VanEck Pharmaceutical ETF
Charts powered in part by Lightweight Charts™ by TradingView.